Literature DB >> 21087777

Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects.

David T Ashley1, Eoin P O'Sullivan, Colin Davenport, Niamh Devlin, Rachel K Crowley, Noel McCaffrey, Niall M Moyna, Diarmuid Smith, Donal J O'Gorman.   

Abstract

An increase in serum osteoprotegerin (OPG) is associated with type 2 diabetes mellitus, the severity of vascular calcification, and coronary artery disease. Obesity is a risk factor for diabetes and cardiovascular disease, but little is known about the relationship between OPG and obesity. The purpose of this study was to determine if changes in body mass index (BMI) and insulin sensitivity influence circulating OPG in healthy subjects. A total of 100 subjects (36 lean, 41 overweight, and 23 obese) with normal glucose tolerance, blood pressure, and electrocardiogram stress test result volunteered for this study. Insulin sensitivity was estimated using a 2-hour oral glucose tolerance test with oral glucose insulin sensitivity analysis. Osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL),soluble receptor activator of nuclear factor-κβ ligand (sRANKL), and adiponectin were analyzed using commercially available enzyme-linked immunosorbent assays. Osteoprotegerin (P < .01) and adiponectin (P < .001) were significantly decreased in the obese compared with lean subjects. There was no significant difference between BMI categories for TRAIL or sRANKL. Controlling for age and sex, there was a significant correlation between OPG and adiponectin (r = 0.391, P < .001), BMI (r = -0.331, P < .001), waist circumference (r = -0.268, P < .01), homeostasis model assessment of insulin resistance (r = -0.222, P < .05), and oral glucose insulin sensitivity (r = 0.221, P < .05). Both OPG and adiponectin were negatively correlated with body weight, BMI, waist circumference, and fasting plasma insulin while being positively correlated with insulin sensitivity (P < .05). Controlling for age, sex, and BMI, TRAIL was positively related to fat mass (r = 0.373, P < .001) and waist circumference (r = 0.257, P < .05). In contrast to patients with type 2 diabetes mellitus, circulating OPG is lower in obese, but otherwise healthy subjects and is positively correlated with indices of insulin sensitivity.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21087777     DOI: 10.1016/j.metabol.2010.10.001

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  23 in total

1.  Portal vein and systemic adiponectin concentrations are closely linked with hepatic glucose and lipoprotein kinetics in extremely obese subjects.

Authors:  Faidon Magkos; Elisa Fabbrini; Bruce W Patterson; J Christopher Eagon; Samuel Klein
Journal:  Metabolism       Date:  2011-05-31       Impact factor: 8.694

2.  TNF-related apoptosis-inducing ligand promotes human preadipocyte proliferation via ERK1/2 activation.

Authors:  Jan-Bernd Funcke; Verena Zoller; Muad Abd El Hay; Klaus-Michael Debatin; Martin Wabitsch; Pamela Fischer-Posovszky
Journal:  FASEB J       Date:  2015-04-09       Impact factor: 5.191

3.  Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease.

Authors:  Michael Estep; Massih Abawi; Mohammed Jarrar; Lei Wang; Maria Stepanova; Hazem Elariny; Amir Moazez; Zachary Goodman; Vikas Chandhoke; Ancha Baranova; Zobair M Younossi
Journal:  Obes Surg       Date:  2011-11       Impact factor: 4.129

Review 4.  Molecular insights into the interplay between adiposity, breast cancer and bone metastasis.

Authors:  Sneha Soni; Meaghan Torvund; Chandi C Mandal
Journal:  Clin Exp Metastasis       Date:  2021-02-16       Impact factor: 5.150

5.  The association of insulin resistance with serum osteoprotegerin in obese adolescents.

Authors:  Joanna Suliburska; Pawel Bogdanski; Ewa Gajewska; Grazyna Kalmus; Magdalena Sobieska; Wlodzimierz Samborski
Journal:  J Physiol Biochem       Date:  2013-05-22       Impact factor: 4.158

6.  Hormone and receptor activator of NF-κB (RANK) pathway gene expression in plasma and mammographic breast density in postmenopausal women.

Authors:  Rachel Mintz; Mei Wang; Shuai Xu; Graham A Colditz; Chris Markovic; Adetunji T Toriola
Journal:  Breast Cancer Res       Date:  2022-04-14       Impact factor: 6.466

Review 7.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

8.  Impaired fasting glucose and diabetes as predictors for radial artery calcification in end stage renal disease patients.

Authors:  Katarzyna Janda; Marcin Krzanowski; Mariusz Gajda; Paulina Dumnicka; Danuta Fedak; Grzegorz J Lis; Piotr Jaśkowski; Jan A Litwin; Władysław Sułowicz
Journal:  Int J Endocrinol       Date:  2013-12-18       Impact factor: 3.257

9.  Association of soluble Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) with central adiposity and low-density lipoprotein cholesterol.

Authors:  Gloria Brombo; Stefano Volpato; Paola Secchiero; Angelina Passaro; Cristina Bosi; Giovanni Zuliani; Giorgio Zauli
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

10.  Association of serum tumor necrosis factor-related apoptosis inducing ligand with body fat distribution as assessed by dual X-rays absorptiometry.

Authors:  Carlo Cervellati; Paola Secchiero; Gloria Bonaccorsi; Claudio Celeghini; Giorgio Zauli
Journal:  Mediators Inflamm       Date:  2014-05-21       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.